LightPath Technologies, Inc. — FY2013 Form 10-K
Reporting period: Fiscal year ended June 30, 2013, compared with fiscal 2012. The filing is an annual report, not a calendar-year 2012 Q4 report; selected fourth-quarter data are also disclosed.
Business context
LightPath designs and manufactures optical components and assemblies, including precision molded glass aspheric optics, infrared lenses, collimators and GRADIUM glass lenses. Its products serve industrial, telecommunications, defense, medical and other markets. Manufacturing is conducted in Orlando, Florida, and Shanghai, China.
Financial performance and liquidity
| Metric | FY2013 | FY2012 |
|---|---|---|
| Revenue | $11.78 million | $11.28 million |
| Gross margin | $5.18 million; 44% | $4.03 million; 36% |
| Operating income (loss) | $210,158 | ($924,299) |
| Net income (loss) | $215,322 | ($864,867) |
| Basic and diluted earnings (loss) per share | $0.02 | ($0.09) |
| Cash provided by operating activities | $556,156 | $405,734 |
| Capital expenditures | $1.10 million | $629,000 |
Revenue increased 4%; units sold in precision molded optics rose 35%. Gross margin improved as manufacturing costs fell, including lower labor, tooling and freight costs. The company reported its first profitable fiscal year, though its accumulated deficit remained approximately $204.4 million. No income tax provision was recorded, primarily because of prior-year tax losses and deferred-tax valuation allowances.
At June 30, 2013, cash and cash equivalents were $1.57 million, current assets $6.08 million, and current liabilities $1.62 million. Total liabilities were $2.95 million, including a $1.10 million warrant liability; the 8% convertible debentures had been converted or repaid and none remained outstanding. After year-end, warrant exercises generated $1.30 million in proceeds; cash was $2.77 million on September 3, 2013. The filing does not provide a clear quantified revenue or earnings forecast for FY2014.
Changes, outlook and risks
- FY2013 gross margin rose to 44% from 36%, while net results improved by about $1.08 million. Operating cash flow increased by approximately $150,000.
- Management expects FY2014 sales growth led by precision molded optics, particularly low-cost Asian applications, infrared products and redesigned collimators. It anticipates further margin gains from production efficiencies and lower material and coating costs.
- Management planned approximately $1.24 million in FY2014 new-product development spending and expected capital expenditures to increase, with the amount dependent on opportunities and circumstances. Current production was at 98% of manned capacity; added equipment and shifts were planned.
- 12-month backlog was $4.14 million at June 30, 2013, down from $4.89 million a year earlier. Management attributed the decline in part to three large orders totaling more than $700,000 delayed into FY2014 Q1.
- Inventory days increased to an FY2013 average of 98 from 76. The company reserved 100% of isolator inventory and decided to stop marketing that product line.
- Five customers each represented at least 5% of FY2013 revenue; the largest was AMS at 10%. Foreign sales accounted for 35% of revenue. Loss of a significant customer could materially reduce revenue.
- Management said resources were adequate for its FY2014 plan but warned that failure to achieve sales and margin targets could require additional financing. If financing were unavailable on acceptable terms, strategic alternatives could be considered.
- Other notable exposures include dependence on some single- or limited-source materials, competitive pressure, production-capacity and working-capital needs, and execution risks in the Raytheon infrared development order. That $1.1 million project was expected to be completed by December 2013; $353,530 was recorded as other receivables for recognized revenue in excess of invoicing.
- Legal proceedings were described as arising in the ordinary course, with management not expecting aggregate losses to have a material adverse effect. Management reported effective disclosure controls and internal control over financial reporting; the auditor did not provide an internal-control attestation.
Important facts for investors to verify
- Reconcile the FY2013 annual profit with the disclosed FY2013 Q4 net loss of $243,765, including the quarterly warrant fair-value and other noncash adjustments.
- Track conversion of the $4.14 million backlog into shipments and revenue, particularly the delayed orders exceeding $700,000, and assess the quality and timing of bookings.
- Confirm post-year-end warrant exercise proceeds, the resulting share issuance and remaining potential dilution; 3.76 million warrants were outstanding at June 30, 2013.
- Monitor cash, working capital, inventory growth, capital spending and whether projected cost and yield improvements support sustained positive operating cash flow.
- Check progress and collection of the Raytheon project receivable, customer concentration, and the effects of discontinuing the isolator product line.